NCT00780403

Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)

A Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 220 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 6 Years – 11 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study was to determine whether children ages 6-11 years prefer desloratadine RediTabs (2.5 mg) or a marketed competitor (Zyrtec® 5 mg Chewable Tablets). The secondary objectives of this study were to compare acceptance of the two attributes, taste and feeling in the mouth, of desloratadine 2.5 mg RediTabs and Zyrtec® 5 mg Chewable Tablets

Conditions

• Allergies

Interventions

Type	Name	Description
DRUG	Desloratadine	desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
DRUG	Zyrtec® (cetirizine)	Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day

Timeline

• Start date: 2005-08-01
• Primary completion: 2005-10-01
• Completion: 2005-10-01
• First posted: 2008-10-27
• Last updated: 2022-02-09
• Results posted: 2010-07-30